Korea Investment CORP Sells 100,600 Shares of Hologic, Inc. (HOLX)

Share on StockTwits

Korea Investment CORP trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 62.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,378 shares of the medical equipment provider’s stock after selling 100,600 shares during the period. Korea Investment CORP’s holdings in Hologic were worth $2,400,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Parnassus Investments CA grew its position in Hologic by 3.4% in the second quarter. Parnassus Investments CA now owns 16,241,334 shares of the medical equipment provider’s stock worth $645,593,000 after acquiring an additional 535,745 shares in the last quarter. Victory Capital Management Inc. grew its position in Hologic by 5.1% in the second quarter. Victory Capital Management Inc. now owns 5,813,464 shares of the medical equipment provider’s stock worth $231,085,000 after acquiring an additional 282,510 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Hologic by 15.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,301,792 shares of the medical equipment provider’s stock worth $85,995,000 after acquiring an additional 301,278 shares in the last quarter. Guggenheim Capital LLC grew its position in Hologic by 4.7% in the first quarter. Guggenheim Capital LLC now owns 1,739,642 shares of the medical equipment provider’s stock worth $64,993,000 after acquiring an additional 77,589 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. grew its position in Hologic by 818.9% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 1,521,695 shares of the medical equipment provider’s stock worth $56,851,000 after acquiring an additional 1,356,091 shares in the last quarter. 98.65% of the stock is owned by institutional investors.

HOLX has been the subject of a number of analyst reports. TheStreet upgraded shares of Hologic from a “c” rating to a “b” rating in a research note on Tuesday, July 31st. Cowen restated a “buy” rating and issued a $45.00 price objective on shares of Hologic in a research note on Wednesday, August 1st. Bank of America boosted their price objective on shares of Hologic from $44.00 to $47.00 and gave the stock a “buy” rating in a research note on Wednesday, August 1st. Jefferies Financial Group restated a “buy” rating and issued a $50.00 price objective on shares of Hologic in a research note on Wednesday, August 1st. Finally, Needham & Company LLC boosted their price objective on shares of Hologic from $43.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, August 1st. Ten investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $44.47.

Shares of Hologic stock opened at $39.64 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.29 and a debt-to-equity ratio of 1.12. Hologic, Inc. has a 1-year low of $35.10 and a 1-year high of $45.09. The firm has a market capitalization of $10.63 billion, a PE ratio of 18.08, a PEG ratio of 1.78 and a beta of 0.65.

Hologic (NASDAQ:HOLX) last released its earnings results on Tuesday, July 31st. The medical equipment provider reported $0.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.02. The firm had revenue of $824.00 million during the quarter, compared to analysts’ expectations of $800.14 million. Hologic had a negative net margin of 2.47% and a positive return on equity of 22.18%. analysts anticipate that Hologic, Inc. will post 2.24 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

See Also: Book Value Of Equity Per Share – BVPS Explained

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Credit Suisse Group Reiterates $4.00 Price Target for Kinross Gold
Credit Suisse Group Reiterates $4.00 Price Target for Kinross Gold
CLSA Reiterates “$125.00” Price Target for YY
CLSA Reiterates “$125.00” Price Target for YY
Clorox  Stock Rating Upgraded by Argus
Clorox Stock Rating Upgraded by Argus
Advanced Micro Devices  Receives New Coverage from Analysts at KeyCorp
Advanced Micro Devices Receives New Coverage from Analysts at KeyCorp
Achillion Pharmaceuticals  Raised to Sell at BidaskClub
Achillion Pharmaceuticals Raised to Sell at BidaskClub
Holly Energy Partners  Downgraded to Underweight at Barclays
Holly Energy Partners Downgraded to Underweight at Barclays


Leave a Reply

 
© 2006-2018 Zolmax.